Localization of Multiple Melanoma Tumor–Suppressor Genes on Chromosome 11 by Use of Homozygosity Mapping-of-Deletions Analysis  by Goldberg, Eleonora K. et al.
Am. J. Hum. Genet. 67:417–431, 2000
417
Localization of Multiple Melanoma Tumor–Suppressor Genes on
Chromosome 11 by Use of Homozygosity Mapping-of-Deletions Analysis
Eleonora K. Goldberg,1 J. Michael Glendening,1 Zarir Karanjawala,1 Anjali Sridhar,1
Graeme J. Walker,1,2 Nicholas K. Hayward,2 Andrew J. Rice,1 Devinda Kurera,1
Yasmine Tebha,1 and Jane W. Fountain1
1Institute for Genetic Medicine, Department of Biochemistry and Molecular Biology, University of Southern California, Los Angeles; and
2Queensland Cancer Fund Research Unit, Joint Experimental Oncology Program of the Queensland Institute of Medical Research and the
University of Queensland, Royal Brisbane Hospital, Herston, Australia
Loss-of-heterozygosity (LOH) studies have implicated one or more chromosome 11 tumor-suppressor gene(s) in
the development of cutaneous melanoma as well as a variety of other forms of human cancer. In the present study,
we have identified multiple independent critical regions on this chromosome by use of homozygosity mapping of
deletions (HOMOD) analysis. This method of analysis involved the use of highly polymorphicmicrosatellitemarkers
and statistics to identify regions of hemizygous deletion in unmatched melanoma cell line DNAs. Regions of loss
were defined by the presence of an extended region of homozygosity (ERH) at 5 adjacent markers and having
a statistical probability of .001. Significant ERHs were similar in nature to deletions identified by LOH analyses
performed on uncultured melanomas, although a higher frequency of loss (24 [60%] of 40 vs. 16 [34%] of 47)
was observed in the cell lines. Overall, six small regions of overlapping deletions (SROs) were identified on chro-
mosome 11 flanked by the markers D11S1338/D11S907 (11p13-15.5 [SRO1]), D11S1344/D11S11385 (11p11.2
[SRO2]),D11S917/D11S1886 (11q21-22.3 [SRO3]),D11S927/D11S4094 (11q23 [SRO4]),AFM210ve3/D11S990
(11q24 [SRO5]), and D11S1351/D11S4123 (11q24-25 [SRO6]). We propose that HOMOD analysis can be used
as an adjunct to LOH analysis in the localization of tumor-suppressor genes.
Introduction
Cytogenetic, molecular, and biological evidence all sup-
port the existence of a melanoma tumor–suppressor
gene(s) on chromosome 11 (Fountain 1998). Deletions of
this chromosome have been identified in 26%–58% of
metastatic melanomas and are also associated with ad-
vanced tumor stage, younger age at presentation, poorer
prognosis, and metastasis to the brain (Trent et al. 1990;
Morse et al. 1992; Tomlinson et al. 1993, 1996; Herbst
et al. 1995; Walker et al. 1995). Predominantly, large
deletions of44 cM (Dib et al. 1996) have been identified
on 11q22-25 (Herbst et al. 1995; Tomlinson et al. 1996),
although additional loss-of-heterozygosity (LOH) find-
ings suggest that another melanoma gene(s) may reside
on 11p or proximal 11q (Tomlinson et al. 1996). Findings
from suppression-of-tumorigenicity studies also support
the existence of an 11q melanoma tumor–suppressor
gene(s) (Robertson et al. 1996), and, recently, we have
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narrowed the location of this gene(s) through the char-
acterization of melanoma hybrids containing fragments
of 11q (Robertson et al. 1999). During the course of this
effort, we identified a previously unsuspected region of
deletion on 11q in a parental melanoma cell line (UACC
903) that was genotypically homozygous at all microsat-
ellite loci ( ) distal to D11S2000 on 11q22.3-23.1.N = 72
This discovery influenced us to use our other unmatched
melanoma cell line DNAs to further narrow regions of
hemizygous deletion on chromosome 11.
Deletions or rearrangements of chromosome 11 have
also been frequently detected in many other cancers,
including those that originate in the breast (Hampton
et al. 1994a; Gudmundsson et al. 1995; Negrini et al.
1995; Tomlinson et al. 1995; Winqvist et al. 1995),
ovary (Foulkes et al. 1993; Davis et al. 1996; Gabra et
al. 1996), cervix (Hampton et al. 1994b; Bethwaite et
al. 1995), lung (Rasio et al. 1995b; Iizuka et al. 1995),
kidney (Call et al. 1990), bladder (Shaw and Knowles,
1995), colon (Keldysh et al. 1993; Connolly et al. 1999),
prostate (Dahiya et al. 1997; Kawana et al. 1997), na-
sopharynx (Hui et al. 1996), oral cavity (Uzawa et al.
1996), and endocrine-associated tissues (Lubensky et al.
1996; Tahara et al. 1996). Although several familial-
predisposition loci, such as the genes for multiple en-
docrine neoplasia type 1 (MEN1; Chandrasekharappa
et al. 1997) and ataxia telangiectasia (ATM; Savitsky
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et al. 1995), have been localized and identified on this
chromosome, deletions detected in many sporadic can-
cers do not consistently or exclusively target these genes.
Progress in narrowing the location of a novel chro-
mosome 11 tumor-suppressor gene(s) has therefore pri-
marily relied on extended LOH analyses (Negrini et al.
1995; Davis et al. 1996; Gabra et al. 1996; Koreth et
al. 1997; Laake et al. 1997; Monaco et al. 1997; Wang
and Evans 1997; Wang et al. 1998; Herbst et al. 1999).
As a whole, these studies suggest that two or more “mul-
tiple” tumor-suppressor genes reside on 11q22-25.
To date, only one homozygous deletion has been iden-
tified (in a lung-cancer cell line) on 11q23 (Wang and
Evans 1997). Given the total number of tumor DNAs
and microsatellite markers screened, the frequency of
homozygous deletions observed on this chromosome is
extremely low. Although this factor has undoubtedly
slowed the identification of an 11q tumor-suppressor
gene, it may also provide a clue as to how the activity
of this gene(s) is modulated during tumor development.
In this regard, results from suppression-of-tumorigenic-
ity studies performed on melanoma (UACC 903; Rob-
ertson et al. 1996, 1999) and cervical cancer (HeLa;
Misra and Srivatsan 1989; Horikawa et al. 1995) both
support the existence of a tumor-suppressor gene on
11q13-23 and suggest that this gene behaves in a dos-
age-dependent manner. It is possible, therefore, that a
single “hit” or haploinsufficiency of a gene on 11q may
be all that is required to provide an evolving tumor cell
with a growth advantage. The 11q13-23 region is also
the home of two maternally imprinted genes, PGL1 and
PGL2, which are predisposition loci for the benign
head-and-neck-tumor syndrome known as “nonchro-
maffin paragangliomas” (Baysal et al. 1997a). Whether
these two loci are targets during the development of any
malignant cancers, including melanoma, remains to be
seen. Like regions on 11p (e.g., the location of the H19,
IGF2, and CDKN1C genes on 11p15.5), certain regions
on 11q may also contain neighboring genes that are
imprinted in the germline and contribute to carcino-
genesis (Rainer et al. 1993; Biran et al. 1994; Matsouka
et al. 1996; Reid et al. 1997). Inactivation of any one
of these genes would also require only a single somatic
event. The potential existence of a dosage-dependent or
imprinted melanoma tumor–suppressor gene(s) on 11q
further influenced us to develop a mapping strategy that
did not rely on the identification of homozygous dele-
tions in tumor cell lines.
In the present report, we describe the use of a method,
which we have denoted as “homozygosity mapping of
deletions” (HOMOD), to identify the location(s) of a
tumor-suppressor gene(s) on chromosome 11. This
method takes into account the probability that a hemi-
zygous chromosomal deletion exists in an unmatched
tumor cell line, on the basis of the number of homozygous
genotypes observed at adjacent loci. Depending on the
heterozygosity values of the markers used, a statistical
probability of .001 (generally, 5 homozygous geno-
types at adjacent markers) was presumed to mark a de-
letion. Only one such significant extended region of ho-
mozygosity (ERH) was observed in constitutional DNAs
analyzed on our patients with melanoma (1/47 individ-
uals screened with 81 markers on chromosome 11; 3,261
independent genotypes evaluated). Overall, 40 mela-
noma cell lines and 124 microsatellite markers were used
to define the locations of six small overlapping regions
of deletion (SROs) on chromosome 11. On a gross level,
the SROs defined in the cell lines accurately reflected
those observed in LOH studies performed, in parallel, on
melanoma and control (constitutional) DNAs from 47
patients, and, in one instance, a very small critical region
(SRO2) was narrowed on 11p11.2 by identification of
deletions in the cell lines that were subsequently con-
firmed in the tumors. Overall, our findings suggest that
at least six melanoma tumor–suppressor genes reside on
chromosome 11: two on 11p and four within the 11q22-
25 region frequently deleted en masse in metastatic mel-
anomas and other cancers.
Material and Methods
Melanoma Tumors and Cell Lines
The melanoma tumors and cell lines used in this study
were obtained from either the Memorial Sloan-Kettering
Cancer Center in New York, NY (designated as “SK-
MEL-#”); the Queensland Institute of Medical Research
in Brisbane, Australia (designated as “QIMR-#”); or the
Massachusetts General Hospital in Boston, Massachu-
setts (designated as “MGH-MEL-#”). Approvals were
obtained from the institutional review boards of these
institutions. Lymphoblastoid cell lines or fresh lympho-
cytes were also paired with each tumor specimen and
served as constitutional controls in LOH analyses. All
but one of the tumors analyzed in this study were clas-
sified as sporadic melanomas. The exception, MGH-
MEL-15, has been determined to carry a germline mu-
tation (M53I) within the CDKN2A gene (referred to as
“M3/6” in Pollock et al. [1998]). Genomic DNAs were
isolated directly from fresh or frozen tissues/cells, by use
of standard techniques (Ausubel et al. 1994).
Microsatellite-Marker Analyses
Primers for microsatellite-marker assays were pur-
chased through Research Genetics or were synthesized
(Gibco BRL) from information available in published
reports (Vanagaite et al. 1995) or the Genome Database
(GDB). Multiplex PCR reactions (10 ml) were performed
on 25–200-ng DNA templates in the presence of 1.0 mCi
a[32P]-dCTP, 1.5 mM MgCl2, 20 pmol each primer (for
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two markers), and 1 U Taq polymerase under the fol-
lowing conditions: initial denaturation at 95C for 3
min; followed by 4 cycles at 94C for 30 s, 60C for 30
s, and 72C for 30 s; then by 26 cycles at 94C for 30
s, 56C for 30 s, and 72C for 30 s; and then by a final
extension at 72C for 5 min. Resultant products were
heated to 95C for 5 min with 10 ml formamide stop
dye, were snap cooled on ice, and were then separated
on 6% denaturing polyacrylamide gels (Sequagel; Na-
tional Diagnostics) run at either 5 W overnight or 100
W for 4–6 h at room temperature. Gels were dried and
exposed to film for 2–16 hours. Results from all markers
were scored independently by two individuals (E.K.G.
and J.W.F.), and critical or ambiguous findings were ver-
ified in repeat assays.
Results
Identification of Gross Critical Regions on
Chromosome 11 in Melanoma Tumors and Cell Lines
Thirty markers were initially chosen to evaluate 47
matched melanoma/control DNAs for LOH on chro-
mosome 11. These markers were concentrated in the
11q22-25 region previously determined to be frequently
deleted in melanoma (Herbst et al. 1995; Tomlinson et
al. 1996) and within regions that, at the time, were under
investigation in our suppression-of-tumorigenicity stud-
ies (Robertson et al. 1999). The same markers were also
used to screen 40 unrelated melanoma cell lines for
ERHs. Sixteen (34%) of 47 melanomas and 20 (50%)
of 40 melanoma cell lines were determined to harbor
deletions that included one or more of these loci (fig. 1).
Deletions in the cell lines were deduced on the basis of
marker-heterozygosity values, with calculated probabil-
ities of .000032 (∼3/100,000) that any set of adjacent
homozygous genotypes ( ) would be observedN = 7–30
in normal control DNAs. For example, the cell line SK-
MEL-146, which had the smallest ERH, was homozy-
gous at seven adjacent markers on 11p (fig. 1C); the
probability of observing this number of homozygous
genotypes by chance is .41 # .22 # .26 # .20 # .28
# .27# .09, or 3.2# 105. By comparison, the avail-
able control DNAs analyzed from the 47 patients with
melanoma were homozygous at 4 adjacent markers
(calculated probabilities of .00136). Additional ERHs
that were disregarded in the cell lines also involved 4
markers and had probabilities similar to those observed
in the control DNAs (data not shown).
Most deletions included, extended from, or resided
within a region flanked by the markers D11S2000 and
D11S969 on 11q22-25 (fig. 1C). Overall, our results
—along with those of others (Herbst et al. 1995; Tom-
linson et al. 1996)—suggest that a minimum of three
melanoma tumor–suppressor genes exist on chromo-
some 11. Notably, one (or two) of these genes reside(s)
on 11p, which was deleted in 10 (21%) of 47 of the
melanoma tumors and in 12 (30%) of 40 of the mela-
noma cell lines. Overall, the regions targeted on this
chromosome were similar in both the melanoma tumors
and the cell lines, providing assurance that the deletions
delineated in the cell lines were primarily reflective of in
vivo events during tumor development.
Four additional factors influenced us to continue to
use HOMOD in an effort to further narrow the critical
regions on chromosome 11. First, we found that results
on the cell lines were often less ambiguous than those
generated on the tumors. While evidence of tumor het-
erogeneity (i.e., an inequality in signal intensities be-
tween alleles at a number of markers) was present in
both sample sets, the existence of contaminating stromal
DNAs had the potential to further confound genotype
assignments in the tumors. Second, the higher frequency
(1.5-fold) of deletion observed in the cell lines suggested
that critical regions might be more rapidly narrowed in
these samples. Third, the cell lines provided inexhaust-
ible sources of DNA that could be screened with an
unlimited number of microsatellite markers. Fourth, our
LOH results for the matched tumor/control DNAs as-
sured us that microsatellite instability (MSI; Boland et
al. 1998) was an infrequent event in melanoma. MSI
was noted at only 6 (0.5%) of 1,255 total genotypes
and in only 4 (8.5%) of 47 melanoma tumors, and oc-
curred only once at a homozygous locus within a region
of deletion on chromosome 11 (data not shown). Thus,
we expected that few of the ERHs defined in melanoma
cell lines would be confounded by MSI.
Heterozygosity Values of Markers
We next investigated how the use of heterozygosity
values obtained from three different sources (Dib et al.
[1996], GDB, and CEPH), versus those calculated on
our mixed population of American and Australian pa-
tients, would affect the probability values used to es-
tablish ERHs in the melanoma cell lines. Overall, we
found that (a) these values did not differ substantially
(e.g., 1.9–2.7-fold for two of the smallest ERHs iden-
tified in the melanoma cell lines SK-MEL-146 and
QIMR-253 [fig. 1C] or 1.7-fold for the largest ERH
identified in the constitutional DNAs) when heterozy-
gosity values from any source were compared and (b)
heterozygosity values from the GDB were often closest
to those obtained on our patients with melanoma. The
latter observation led us to use GDB heterozygosity val-
ues in our extended HOMOD analyses whenever pos-
sible. These comparisons also enabled us to establish the
maximum probability of a significant ERH as .001,
given the range of values (.00117–.00200) calculated for
the largest ERH observed in the control samples. The
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value of .001 was also concordant with the (average)
probability of observing an ERH that included5 mark-
ers (i.e., [.25]5, or .00098).
Density and Relative Order of Markers
An additional 94 microsatellite markers (for a total
of 124 markers) were used to screen the 40 melanoma
cell lines for hemizygous deletions or ERHs on chro-
mosome 11. Three of these 94 markers have not pre-
viously been described and were designed from high-
throughput genomic sequence (htgs) available on two
P1-derived artificial chromosomes (PACs; pDJ149k2
and pDJ360p17 [GenBank accession numbers
AC001234 and AC001235, respectively]) located on
11q23.1-23.2 (table 1). Most of the markers used were
concentrated on 11q and proximal 11p, specifically
within the regions immediately flanking the centromere
and between 11q22-25. Coverage was especially dense
between D11S2000 and D11S969, where markers
( , noninclusive) were analyzed at average inter-N = 78
vals of 310–380 kb (James et al. 1994; Arai et al. 1996;
GDB). Marker order was established using physical-
mapping information obtained from radiation hybrids
as well as YACs, PACs, and cosmids (James et al. 1994;
Vanagaite et al. 1995; Arai et al. 1996; Baysal et al.
1997b, 1998; GDB; Whitehead Institute for Biomedical
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Figure 1 Gross deletions on chromosome 11 in melanoma tumors and cell lines. A, LOH examples at the locus D11S35 on 11q22.2.
Constitutional (C) and matched tumor (T) results are shown for six individuals. Tumor designations are shown below each panel, and deleted alleles
are indicated (arrows). B, Microsatellite-marker analysis for 10 melanoma cell line DNAs at D11S35. Heterozygous (denoted by two plus signs
[]) and homozygous (denoted by a single plus sign []) genotypes are indicated. Abbreviated cell-line designations are provided at the top of
the panel. C, Subchromosomal deletions identified on chromosome 11 in 47 melanoma tumors and 40 melanoma cell lines screened with a panel
of 30 microsatellite markers. Tumors ( ) or cell lines ( ) presumed to have lost an entire copy of chromosome 11 (or harboring an ill-N = 7 N = 8
defined critical region resulting from tumor heterogeneity or a high level of normal DNA contamination [ tumors]) are not shown. An ideogramN = 2
of chromosome 11 is provided (right) with a list of markers and genes (underlined [red]). The relative order of markers/genes is shown from 11pter-
qter, and the approximate cytogenetic location of certain genes/markers is indicated (James et al. 1994; Rasio et al. 1995a; Vanagaite et al. 1995;
Chandrasekharappa et al. 1997; Kawana et al. 1997; Li et al. 1997; Reid et al. 1997; Wang et al. 1998). Heterozygosity values are provided in
parentheses (GDB; Vanagaite et al. 1995; Dib et al. 1996). Abbreviated tumor or cell-line designations are listed at the top. Deletions in each tumor/
cell line are boxed in yellow. Unblackened circles denote a heterozygous genotype; blackened circles, LOH; diagonally striped circles, a homozygous
genotype; and absence of a circle, an inconclusive or undetermined result. Three overlapping regions of deletions (black vertical bars) were identified
in this study and were compared with regions defined in two previous LOH studies performed on melanoma (checkered bars [Tomlinson et al.
1996]; horizontally striped bar [Herbst et al. 1995]). The existence of at least three critical regions—pter toD11S1324 (proximal boundarydetermined
by Tomlinson et al. [1996]), D11S554–D11S901, and NCAM–D11S1316 (dark gray–shaded boxes)—is supported by two or all three of these
independent studies; a fourth region, D11S2000–D11S2179 (light gray–shaded box), may also exist near the ATM gene.
Research/MIT Center for Genome Research; E. K.
Goldberg, J. Salcedo, J. Welch, N. K. Hayward, and J.
W. Fountain, unpublished data). In certain instances
(e.g., proximal to D11S2000 and distal to MLL1) ge-
netic-mapping information was also used to orient
some loci (Dib et al. 1996). The location of the DNA-
damage checkpoint–control gene, CHK1 (Sanchez et
al. 1997), relative to microsatellite markers on 11q24-
25, was also determined through analyses performed
on YACs (fig. 1C) (E. K. Goldberg, J. Salcedo, J. Welch,
N. K. Hayward, and J. W. Fountain, unpublished data).
Identification of Two Critical Regions on 11p
In total, 27 markers were screened on 11p and the
pericentromeric region of 11q, to determine the location
of a melanoma tumor–suppressor gene(s) on 11p and/or
proximal 11q. Markers were chosen primarily because of
their proximity to the centromere and usefulness in dis-
tinguishing deletions on 11p from those on 11q. Geno-
types were scored as heterozygous or homozygous at each
locus in the 40 melanoma cell lines (fig. 2A). Overlaps
between significant ERHs (probabilities of .001, which
were calculated primarily with GDB heterozygosity val-
ues) revealed two independent SROs on 11p (fig. 2B and
2C). A subset of markers from this region ( ) wasN = 18
also used to screen for LOH in the matched melanoma/
control DNAs. Both SROs were supported by distinct
deletions identified in the melanoma tumors (fig. 2B and
2D). Whereas SRO1 was estimated to span a large region
of 14–16 Mb on 11p13-15.5 (GDB), SRO2 was presumed
to span a region of only 200 kb on 11p11.2. The size of
the latter SRO was based on the existence of a nonchi-
meric YAC clone (y962g6) in the CEPH YAC library that
was positive for the contiguous markers D11S436,
D11S1344, D11S4174, and D11S1385 and only 200 kb
in size (Whitehead Institute for Biomedical Research/MIT
Center for Genome Research). A known metastasis-sup-
pressor gene, KAI1 (Dong et al. 1995)—as well as a pu-
tative liver tumor–suppressor gene (Coleman et al.
1997)—map within or close to this region.
Identification of Four Critical Regions on 11q
Ninety-seven additional markers (distal to D11S901
on 11q14; fig. 2B) were also screened on the 40 mela-
noma cell lines to search for smaller ERHs on 11q. Re-
sults were compiled and are shown in figure 3. In total,
three of the melanoma cell lines (SK-MEL-113, SK-
MEL-133, and QIMR-383) originally presumed to be
deleted for an entire copy of chromosome 11 were now
known to harbor at least two distinct deletions: one (or
two) on 11p and one on 11q (figs. 2B and 3). Four
additional significant ERHs were also identified in the
cell lines QIMR-472, QIMR-418, and SK-MEL-13 (fig.
3). These ERHs each spanned 7–10 adjacent loci and
had probability values of 1.38# 104 (table 2). Over-
laps between the ERHs, along with LOH data generated
for the tumors (in the case of SRO3), served to define
four distinct critical regions on 11q21-25 that ranged in
size from 1 Mb (SRO5 and SRO6) to 12–14 Mb
(SRO3 and SRO4). Notably, no homozygous deletions
were identified in any of the 40 melanoma cell lines.
A subset of these 11q markers ( ) was also usedN = 55
to screen for LOH in the 47 melanoma tumors. Although
no definitive deletions were identified, subtle differences
between allele intensities were noted in five tumors with
markers from within SRO4 (data not shown). As a
whole, these tentative deletions centered on the marker
D11S897. This marker was also scored as being retained
in the melanoma SK-MEL-06, which was originally pre-
sumed to harbor three independent and extensive de-
letions on chromosome 11 (fig. 1C). Since this tumor
sample has previously been determined to have levels of
stromal contamination of ∼50% (Gonzalgo et al. 1997;
see fig. 1A), there is the potential that D11S897 is ac-
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Table 1
Microsatellite Markers Developed from DNA Sequence Available on PACs pDJ149k2 and pDJ360p17
Marker Repeat Primer Sequence
Sizea
(bp) Heterozygosityb No. (Frequencies) of Allelesc
ZK96.9 (CA)21 Forward: 5
′-CTGTCAGTGAAATGGCATGG-3′
Reverse: 5′-GCAAACACCTTCCATCACCT-3′
213 .74 ( )N = 38 9 (.014, .014, .014, .200, .129,
.100, .443, .057, and .029)
ZK119 (CA)12 Forward: 5
′-ATCCAGCCAAGTTATCTCGC-3′
Reverse: 5′-GAACCTGTTGTGCATGTTGG-3′
218 .55 ( )N = 22 7 (.023, .681, .023, .136, .023,
.090, and .023)
ZK21.2 (CA)20 Forward: 5
′-AACTGAAGAGGTGGGTTGGA-3′
Reverse: 5′-TGCTCTGGAATGAAAGCTCA-3′
216 .87 ( )N = 38 5 (.105, .237, .395, .066, and .197)
NOTE.—Sequence contigs on pDJ149k2 (179 kb) and pDJ360p17 (169 kb) were obtained from the htgs database (GenBank accession
numbers AC001234 and AC001235, respectively). Contigs were screened for di-, tri-, and tetranucleotide repeat units 7. A total of nine
such sequences were identified at locations 20401, 21661, 96961, and 119881 in pDJ149k2 and at locations 15601, 21241, 40081,149461,
and 155461 in pDJ360p17. Primers were designed to amplify all nine repeats (Primer3 program; Whitehead Institute for Biomedical
Research/MIT Center for Genome Research) and were tested on chromosome 11 YACs and hybrid DNAs (Robertson et al. 1999) to
assure their location. Products amplified from the 20401 and 15601 repeats were not specific for loci on chromosome 11. Of the remaining
candidate loci, only primers designed for the 96961 (ZK96.9), 119881(ZK119), and 21241 (ZK21.2) repeats produced reliable and easily
scored genotypes.
a Size of fragment amplified from either pDJ149k2 or pDJ360p17.
b Number of independent control genotypes assessed (N) is indicated in parentheses.
c Number of alleles identified in control lymphocyte/lymphoblastoid DNAs; order of frequencies is presented from smallest to largest
allele.
tually homozygously deleted, rather than retained, in
SK-MEL-06. Evidence of overlapping deletions within
the other SROs on 11q was less convincing (data not
shown).
HOMOD Probabilities with Increasing Marker Density
By the end of our analyses on chromosome 11, the 47
matched melanoma/control DNAs had been screened
with 81 independent microsatellite markers. Of these
markers, 73 were analyzed in common on the 40 mela-
noma cell line DNAs, whereas the remaining 8 markers
(D11S922, D11S860, D11S861, D11S1883, D11S1889,
D11S1365, D11S1345, and D11S1328) were scored ex-
clusively on the tumors. Results obtained on the consti-
tutional DNAs from patients with melanoma provided us
with the opportunity to reassess the probability of an
ERH, given a significant increase in marker density (from
30 to 81 markers). While the markers were now separated
by average distances of ∼1.7 Mb, in certain regions (e.g.,
between D11S2000 and D11S1316; fig. 1C), they were
more closely spaced at intervals of 580–650 kb (James et
al. 1994; GDB). Overall, a total of 3,261 independent
genotypes were scored and, on average, 40 genotypes
were evaluated at each locus. Although the number of
ERHs observed increased with increasing marker density,
the probability of a constitutional ERH of 5 markers
remained remarkably consistent with what was previously
observed using the original 30 markers (i.e.,.00135 vs.
.00136). One exception, however, was identified in an
individual (matched tumor/control pair MGH-MEL-13)
whose constitutional (lymphocyte-derived) DNA was
homozygous at seven adjacent loci, spanning a distance
of ∼2 Mb (GDB) between markers D11S1336 and
D11S2090. This ERH overlapped an ERH identified in
an unrelated melanoma cell line (SK-MEL-13) and is lo-
cated between SRO4 and SRO5 on 11q23-24 (fig. 3).
MSI
The frequency of MSI in the 47 matched melanoma/
control DNAs was also reevaluated after analysis with
81 markers. A total of 25 cases of MSI were identified
(data not shown). This frequency of MSI (25 [.83%] of
3,011 tumor genotypes evaluated) was, again, consistent
with the frequency of MSI (.5%) observed with the orig-
inal 30 markers. Of a total of 47 tumors, in only one
(QIMR-976) was MSI identified at multiple loci (N =
); the remaining examples ( ) were unique to each9 N = 16
tumor and were almost exclusive for each locus. MSI
was detected twice, at only 4 (D11S1354, D11S1787,
D11S1792, and D11S2090/AFM210ve3) of the 81 loci.
Of the 25 cases of MSI, 16 were identified at hetero-
zygous loci (2 of which were also scored as reduced),
whereas the remaining 9 cases were homozygous. Al-
most all of the cases of MSI (24 [96%] of 25) involved
the addition or deletion of one (19 [76%] of 25) or two
(5 [20%] of 25) dinucleotide repeat(s). These findings,
as well as the lack of evidence of MSI in cell lines known
to be extensively deleted on either 11p or 11q, further
assured us that the genotype assessments made on the
melanoma cell lines were accurate.
Discussion
In the present report, we have refined a molecular ap-
proach for the localization of novel tumor-suppressor
genes on the basis of the identification of hemizygous
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Table 2
HOMOD Probabilities for ERHs on 11q
HOMOD PROBABILITIES FOR
CELL LINE SRO3 SRO4 SRO5 SRO6
QIMR-253 … 9.72 # 1024 a … …
QIMR-472 .00112 … … 3.38 # 106
QIMR-418 … … 3.24 # 106 b
SK-MEL-13 2.11 # 10 6 … 1.38 # 104 a …
NOTE.—Probabilities were calculated using heterozygosity values provided in
figure 3. Only ERHs with significant (.001) or borderline (italics) probabilities
are shown.
a The findings from the present study—as well as those from GDB and GenBank
database searches—indicated that the D11S4090/NCAM (within SRO4) and
D11S2090/AFM210ve3 (just proximal to SRO5) primers recognize the same locus
or are in strong linkage disequilibrium with each other. Each of these marker sets
was considered as one locus in marker counts and probability calculations.
b This ERH extends through (and serves to define) both SRO5 and SRO6.
deletions in unmatched tumor cell lines by use of highly
polymorphic microsatellite markers and statistics. We
have designated this approach as “homozygosity map-
ping of deletions,” or “HOMOD,” because it is similar
in concept to the homozygosity-mapping methods used
to identify recessive disease genes in isolated populations
(Sheffield et al. 1995). This approach further extends the
usefulness of tumor cell lines in gene-cloning projects,
by allowing them to serve as critical reagents in both
hemizygous—as well as homozygous—deletion screens.
Since these projects routinely involve efforts to identify
homozygous deletions in tumor cell lines, findings akin
to those described in the present study may exist in many
laboratories but may remain largely unscrutinized.
While the screening of tumor cell lines for confined hemi-
zygous deletions with microsatellite markers has been
performed retrospectively—or after the identification of
a critical tumor-suppressor gene (Liu et al. 1995; Cas-
tellano et al. 1997)—we believe this is the first time it
has been used to assist in the mapping of a novel tumor-
suppressor gene(s).
We applied HOMOD analysis to a region of the ge-
nome—namely, chromosome 11—that is known to be
deleted in many human cancers, including melanoma.
Identification of the location of a melanoma tumor–
suppressor gene on chromosome 11 has been especially
challenging, given the large size of most deletions and
the existence of at least three targets (Herbst et al. 1995;
Tomlinson et al. 1996). Conclusively, defining a critical
region on this chromosome (especially within 11q22-
25) has been historically difficult in other cancers as
well, presumably because of these same or similar com-
plications. In such instances, many markers may need
to be analyzed to identify or narrow the location of a
critical gene. This would potentially preclude the use of
microdissected tumor DNAs, which are often limited in
quantity. In addition, during the course of the present
study, we discovered evidence of tumor heterogeneity
on chromosome 11 in both our uncultured melanoma
tumors and cell lines (E.K.G. and J.W.F., unpublished
data). Heterogeneity, which was readily identified via
dosage differences between marker alleles, was observed
in more than one-fourth of the cell lines that were scored
as being largely retained on chromosome 11. In another
unrelated melanoma cell line analyzed along with a
matching control, we have also identified a clonal (pres-
ent in all cells) deletion on 11q as well as a nonclonal
(heterogeneous) deletion on 11p (E.K.G. and J.W.F., un-
published data). Thus, there is evidence that heteroge-
neous populations of tumor cells may coexist in culture.
This factor has the potential to even further complicate
the localization of tumor-suppressor genes, especially in
uncultured tumor specimens in which both tumor het-
erogeneity and stromal contamination may be present.
Tumor cell lines have been shown, in several contexts,
to appropriately mimic their uncultured counterparts
(Forozan et al. 1997; Wistuba et al. 1999), and they
have been especially critical reagents for the localization
and identification of tumor-suppressor genes (Kamb et
al. 1994; Steck et al. 1997). They are also useful in
biological and biochemical analyses designed to verify
or elucidate the function of a suppressor gene once it
has been identified (Morin et al. 1997; Robertson et al.
1998; Walker et al. 1999). Knowing what genetic al-
terations exist within these cell lines has, most recently,
made them especially powerful reagents for discrimi-
nating between the benefits of anticancer agents (Kohn
1996; Heise et al. 1997). The fact that certain genetic
alterations occur at a higher frequency in tumor cell
lines (e.g., those involving chromosome 9, as reviewed
in Walker et al. [1998]) than in uncultured tumors has
also contributed to the more rapid identification of par-
ticular tumor-suppressor genes, such as the cyclin-de-
pendent kinase inhibitor 2A (CDKN2A) gene (Kamb et
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al. 1994). Even given the caveat that not all alterations
observed in tumor cell lines may have arisen in vivo (or
even if they did, may not target a critical gene), knowl-
edge of the detailed genetic characteristics of these cell
lines could be of potential value to ongoing and future
studies aimed at the testing of new therapeutics.
Overall, HOMOD analysis enabled us to identify six
critical regions on chromosome 11, through the analysis
of 40 melanoma cell lines with 124 microsatellite mark-
ers. As in our previous CDKN2A analyses performed
on chromosome 9 (Flores et al. 1996), we discovered
that deletions on chromosome 11 occurred at a higher
frequency (or were more readily detectable) in mela-
noma cell lines than in uncultured melanomas. Specif-
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Figure 2 Two distinct SROs defined on 11p by use of HOMOD analysis. A, Examples of microsatellite-marker results on 11p and proximal
11q. Abbreviated cell-line designations are provided at the top of each panel for six melanoma cell lines. Heterozygous (denoted by two plus
signs []) or homozygous (denoted by a single plus sign []) genotypes are indicated under each panel. For D11S1385 and D11S1298,
examples of microsatellite instability (R [where R denotes replication error]) are shown on the cell lines QIMR-253 and SK-MEL-247,
respectively. B, Terminal and interstitial ERHs and regions of LOH defined on 11p in the melanoma cell lines and confirmed in the melanoma/
control tumor pairs. Only cell lines with significant ERHs (probabilities .001) or tumors with confined deletions are shown. An ideogram of
11pter-11q22 is provided on the left, along with a list of 27 markers and genes (underlined [red]); the cytogenetic location of several of these
loci is indicated on 11p or 11q. The relative order of the markers was determined using the radiation-hybrid map presented by James et al.
(1994) and other physical maps (from GDB and the Whitehead Institute for Biomedical Research/MIT Center for Genome Research) as well
as information provided by Kawana et al. (1997) and Coleman et al. (1997) for the placement of markers around the KAI1 locus. Heterozygosity
values for the markers are provided in parentheses, and, with the exception of D11S1784, were obtained from either the CEPH database
(D11S1385 only), Research Genetics (D11S436 only), or GDB (all others). Although the heterozygosity value for D11S1784 is reported as
0.20 in Dib et al. (1996) and as 0.26 by CEPH, we found this marker to be significantly more polymorphic in our samples. A heterozygosity
value of 0.49 (18 of 37) was calculated from control genotypes on our patients with melanoma and is the value we used for determination of
the probability of an ERH. Cell-line and tumor designations are provided at the top, and significant ERHs or regions of LOH are boxed in
yellow. Other insignificant (in QIMR-383) or borderline (in SK-MEL-37) ERHs identified in the cell lines are indicated by unblackened boxes.
Unblackened circles denote a heterozygous genotype; blackened circles, LOH; diagonally striped circles, a homozygous genotype; and absence
of a circle, an inconclusive or undetermined result. Two SROs (SRO1 and SRO2 [gray boxed regions]) on 11p were defined by overlapping
ERHs or regions of LOH in the cell lines and tumors. The putative gene in SRO2 is assumed to span the locus D11S4174 as a result of the
existence of nonoverlapping ERHs in the cell lines QIMR-96L and SK-MEL-28. C, Probability values calculated on the 11p ERHs identified
in the 10 melanoma cell lines shown in B. Heterozygosity values were converted to homozygosity values and were used to determine the
probability of each ERH. For example, the smallest significant ERH was identified in QIMR-96L and had a probability of 6.03 # 104 (or
.19# .35# .09# .53# .19). As expected, no significant ERHs that included !5 adjacent loci were identified. Even though the ERHs defined
in SRO2 in QIMR-383 and SK-MEL-37 spanned five or six loci, respectively, their probability values (italics) were not deemed significant. D,
Noncontiguous deletion on 11p, defined by LOH analysis in the matched control (C) and tumor (T) pair on patient QIMR-888. In the melanoma
obtained from this patient, alleles were deleted (arrows) at loci D11S554 and D11S1385 but were retained at flanking markers D11S935 and
D11S1298. The region of overlapping deletions identified in the tumors (8–11 Mb from D11S1344 to D11S1298; GDB) included SRO2 and
served to support the findings from the melanoma cell lines.
ically, ERHs or deletions were confidently identified in
24 (60%) of 40 of our melanoma cell lines, compared
with only 16 (34%) of 47 of the tumors. Overlaps be-
tween ERHs were then primarily used to establish the
boundaries of six SROs (SRO1–SRO6) on chromosome
11. Three of these SROs were 1 Mb and suggested
that HOMOD analysis, like LOH analysis, could be
successful in precisely pinpointing the location of a tu-
mor-suppressor gene. A complete absence of homozy-
gous deletions in these cell lines adds credence to the
possibility that a critical gene(s) on this chromosome
behaves in a dosage-dependent manner, as implied by
the results of previous functional studies (Misra and
Srivatsan 1989; Horikawa et al. 1995; Robertson et al.
1996, 1999).
The critical regions or SROs identified in the current
study are also supported by findings from two other
independent LOH studies of melanoma (Tomlinson et
al. 1996; Herbst et al. 1999). In the most recent study
by Herbst et al. (1999), two critical regions were put
forward as primary targets on 11q23; both are con-
tained in their entireties within SRO4. One of these
regions centers on the marker D11S925, whereas the
other maps between D11S1347 and D11S4142. The
results of the second (more limited and older) LOH
study performed on melanoma are also broadly sup-
portive of these assignments and specifically implicate
the region between NCAM and D11S29 (in SRO4) as
being the most-likely location(s) of a melanoma tu-
mor–suppressor gene(s) on 11q (Tomlinson et al. 1996).
Our own functional (i.e., suppression-of-tumorigenic-
ity) data also support the localization of a tumor-sup-
pressor gene within SRO4 between markers D11S1786
and D11S2077 (Robertson et al. 1999). This same con-
fined region overlaps a region that has been indepen-
dently identified, via both molecular and biological
means, in lung cancer (Iizuka et al. 1995; Murakami et
al. 1998; Wang et al. 1999).
Recently, an attractive candidate tumor-suppressor
gene—the serine/threonine protein phosphatase subunit
locus (PPP2R1B)—has been localized on 11q23 and
implicated in lung and colon cancer (Wang et al. 1998).
Although this gene maps on the proximal edge of SRO4,
the upper boundary defined by Herbst et al. (1999) for
the location of a critical gene within this region (i.e.,
D11S1347) potentially excludes PPP2R1B as a primary
target in melanoma. Similarly, the recently identified
PGL1 locus, which encodes the succinate-ubiquinone
oxidoreductase subunit D (SDHD) protein, also resides
proximal to D11S1347, diminishing its attractiveness
as a candidate gene for melanoma (Baysal et al. 2000).
The down-regulation of three known genes located
within SRO4—namely, the neural-cell adhesion mole-
cule (NCAM), the promyelocytic leukemia zinc finger
(PLZF), and the myeloid/acute lymphoblastic leukemia
(MLL1) genes—may also contribute to the development
of melanoma and/or a number of the other cancers ex-
hibiting frequent loss on 11q23. There is already evi-
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Figure 3 Four distinct SROs defined on 11q13-qter by use of
HOMOD analysis. Only melanoma cell lines (top) with significantERHs
and breakpoints in this region are shown. Markers ( ) and genesN = 102
(underlined [red]) are listed in order (left). In the case of the PLZF gene,
the locations of the first (PLZF[1]) and last (PLZF[6]) exons of this gene
are indicated. Heterozygosity values for polymorphic loci are provided
in parentheses and come from GDB, with the following exceptions: (1)
values for D11S2000, D11S1787, D11S1778, D11S1391, D11S965,
and D11S1992 are from the CEPH database; (2) values for D11S2179,
D11S2180, and D11S2003 are from Vanagaite et al. (1995); (3) values
for D11S1786, D11S1792, D11S1752, and D11S968 are from Dib et
al. (1996); (4) values for 17e5/CA and 17e5/GAAA are from Baysal et
al. (1997b); and (5) values for AFM289yc9, ZK96.9, ZK119, ZK21.2,
D11S2077, D11S964,D11S2090,AFM210ve3,D11S1894,D11S1884,
and D11S439 were calculated, in the present study, from melanoma
patient control genotypes. Unblackened circles denote a heterozygous
genotype; blackened circles, a homozygous genotype; and absence of a
circle, an inconclusive or undetermined result. Significant ERHs (prob-
abilities .001) are boxed in yellow, whereas a borderline ERH (prob-
ability .00112) in the cell line QIMR-472 is indicated by an unblackened
box. Four SROs (SRO3–SRO6) are shaded in gray. The proximalbound-
ary of SRO3 was established by LOH studies performed on melanoma
tumors (figure 1). Two critical regions identified on 11q23 in an inde-
pendent LOH study performed on melanoma (from D11S1347–
D11S4142 and D11S528–D11S1345 [a marker just proximal to
D11S1336]) are indicated by unblackened boxes within SRO4 (Herbst
et al. 1999). A region that we recently found to be associated with
suppression of tumor formation in the melanoma cell line UACC 903
(abbreviated as “903”; D11S1786–D11S2077) is also indicated as a
light gray–shaded area within SRO4 (Robertson et al. 1999).
dence that disruption or inactivation of these genes pos-
itively influences cell growth or, in the case of NCAM,
invasion and metastasis (Edvardsen et al. 1994; Arak-
awa et al. 1998; Owens et al. 1998; Shaknovich et al.
1998; Croce 1999; Perl et al. 1999). Therefore, it is
possible that loss of this region is associated with the
down-regulation or haploinsufficiency of a number of
growth inhibitory genes, rather than being ultimately
directed at the inactivation of a single target.
Aside from SRO4, which remains a relatively large
(14-Mb) region, findings from the present study enabled
us to narrow the locations of four other chromosome
11 tumor-suppressor genes implicated in melanoma.
This included the refinement of three 11q critical regions
recently identified by Herbst et al. (1999), as well as an
11p region originally defined by Tomlinson et al. (1996).
The most proximal target on 11q (SRO3) is now limited
to a region of 7–8 Mb between 11q22.2-22.3 (GDB),
flanked by the markers D11S35 and D11S1886. We
have also provided preliminary evidence for the nar-
rowing of two more distal targets on 11q24-25 to
regions of 1 Mb. It is of note that these two regions
(SRO5 and SRO6) each contain an attractive candidate
gene (CHK1 and ETS1, respectively). While CHK1 en-
codes a protein kinase that controls transition from the
G2 to M phase of the cell cycle (Sanchez et al. 1997),
expression of ETS1 has recently been shown to inhibit
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tumor growth as well as induce apoptosis in colon-
cancer cells (Huang et al. 1997; Li et al. 1999). Finally,
our HOMOD analyses have been successful in precisely
pinpointing the location of a fourth tumor-suppressor
gene on 11p11.2. This last critical region (SRO2) is
supported by 11 independent ERHs/deletions that
jointly overlap a common region of 200 kb. The dis-
covery that one of these ERHs exists within a melanoma
cell line (MelJuSo; Miele et al. 1996) routinely used in
suppression-of-tumorigenicity/metastasis analyses pro-
vides us with the immediate opportunity to assess the
biological roles of two potential candidate genes within
this region—KAI1 (Dong et al. 1995) and an unrelated
liver tumor–suppressor gene (Coleman et al. 1997)—in
melanoma tumor growth, invasion, and metastasis.
Although seemingly unrelated to cancer development,
our study is also supportive of recent discoveries re-
ported by Broman and Weber (1999). These investi-
gators have determined that large ERHs can exist within
the constitutions of both consanguineous and outbred
individuals. Through genetic modeling and analyses
performed on six CEPH families, their results suggested
that up to 20% of all outbred individuals within a pop-
ulation may harbor at least one significant ERH within
their genomes. The general design of their study as well
as the conclusions drawn from their efforts, including
the density of markers screened (one per ∼0.5 cM vs.
580–650 kb, respectively) and the size of a significant
ERH (5–6 adjacent markers), are remarkably similar
to ours. Even though the manner in which significance
was calculated differed between the two studies (LOD
scores versus probabilities determined via the multipli-
cation of marker-homozygosity values), both revealed
that 2%–3% of outbred individuals were constitution-
ally homozygous for regions spanning 7–9 adjacent
markers on chromosome 11 (see the supplemental table
in Broman and Weber [1999]). The single significant
(constitutional) ERH identified on 11q23.3-24 in the 47
unrelated individuals analyzed in our study had a prob-
ability of , which differed by 27-fold from54.9# 10
that of all other control ERHs (defined by 5 markers
with probabilities.00135) observed in our sample set.
Importantly, there was no overwhelming evidence that
this particular individual was a product of consanguin-
ity, since he/she was constitutionally heterozygous at 50
(.74) of 68 genotypes evaluated elsewhere on chromo-
some 11, where the average heterozygosity value for the
81 analyzed markers was 0.73 (Vanagaite et al. 1995;
Dib et al. 1996; Baysal et al. 1997b; GDB; CEPH; the
present study). By use of the methodology of Broman
and Weber (along with allele frequencies from CEPH
or those calculated from our patient control DNAs; data
not shown), this constitutional ERH has now been de-
termined to have a LOD score of 4.45–5.09. This LOD
score reaches the minimum significance level established
by Broman and Weber (1999), where the smallest ERH
had a LOD score of 4.70 and extended across six mark-
ers. If our results were extrapolated across the entire
genome (of which chromosome 11 represents ∼5%),
then one might expect to detect a significant ERH in
∼40% of individuals within an outbred population. The
relationship of these ERHs to disease (e.g., cancer) risk
currently remains unknown. Likewise, the molecular or-
igins of these ERHs are not certain and could be at-
tributable to either consanguinity, confined uniparental
isodisomy (Martin et al. 1999), or germline deletion.
The fact that our constitutional ERH (D11S1336–
D11S2090) spans a recently identified fragile site on
11q23.3-24 is potentially supportive of either of the
latter two possibilities (Tunnacliffe et al. 1999). This
region of the genome may be more prone than others
to breakage and/or rearrangement without any obvious
phenotypic consequence.
Even though the frequency of homozygous segments
within human genomes may be higher than was pre-
viously suspected, it still does not reach a level of sig-
nificance that should limit the success of HOMOD. Pre-
dictably, the power of HOMOD will also increase with
time, as genomic maps become denser and there is less
ambiguity in marker order. HOMOD screens could ul-
timately be performed on DNA microarrays containing
single-nucleotide polymorphism (SNP) variants (Lander
1999), as long as a dense set of markers existed that
showed minimal evidence of linkage disequilibrium. By
screening tumor cell line DNAs with a significant num-
ber of available markers, one should be able to rapidly
define the locations of most tumor-suppressor genes fre-
quently targeted in human cancers. Once defined, it then
becomes a routine exercise to determine (via mutation/
methylation/expression studies) the candidacy of genes
located within each small region. The true target could
then be functionally verified in a cell line already known
to be devoid or haploinsufficient for its product. Ulti-
mately, computer databases that would contain com-
prehensive (total-genome) information on particular cell
lines may evolve from such analyses. As our understand-
ing of human cancer continues to increase, these da-
tabases could provide us with valuable clues as to the
effectiveness of certain therapeutics, given the combi-
nation of genetic (and epigenetic) aberrations present in
a tumor cell.
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